Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication in the class of immune checkpoint inhibitors. It selectively binds and blocks the programmed death-1 receptor on T cells, thereby facilitating their activation. From Wikipedia
The five-minute nivolumab jab, approved by the MHRA, will benefit 1,200 patients monthly, replacing IV infusions for 15 cancer types at no additional cost.
